According to the U.S. Centers for Disease Control and Prevention, about 8 million healthcare workers (HCWs) are potentially exposed to hazardous drugs (HD) and minimizing surface contamination is critical for protecting their health. International guidelines and standards recommend the use of closed system drug-transfer devices (CSTD) for preparation and administration of HD to reduce exposure. In a study conducted at Emory Healthcare’s Winship Cancer Institute, they tested the effects of the BD PhaSeal™ Optima, a newly designed CSTD, and a novel HD testing device, the BD® HD Check system on HD contamination and detection at two chemotherapy infusion centers. Collectively, the BD PhaSeal™ Optima and BD® HD Check may help to reduce HD contamination and provide real-time measures of contamination, respectively. This presentation will describe an approach to select and implement a CSTD in a multisite health-system, review real-world study results on reduction of HD surface contamination, including best practices for ongoing HD detection and monitoring to improve HCW and patient safety.
- Describe the process by which a large, multisite health-system selected and implemented a new closed system drug-transfer device (CSTD)
- Discussion on best practices for ongoing detection and monitoring of hazardous drug (HD) surface contamination
- Review real-world study results on reduction of HD surface contamination 1-year post-implementation of a novel CSTD